Skip to content
    J.P. Morgan logo

    J.P. Morgan

    J.P. Morgan is a pre-seed to growth stage investment firm. It has made 71 investments. 30% of their portfolio is in Fintech. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $184.0M (across 83 rounds with reported amounts).

    Find people at J.P. Morgan on Goldilocks AI

    Portfolio

    71

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    2

    Team

    AB

    Anjali Balani

    Managing Director, US head of the Investment Specialist team

    PC

    Philip Camporeale

    Managing Director, Chief Investment Strategist

    RM

    Richard Madigan

    Chief Investment Officer

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    93 investments
    CompanyRoundAmountDate
    Albert Invent logoAlbert InventSeries B$55MOct 2026
    Capitolis logoCapitolisSeries E$120MOct 2026
    Lumilens logoLumilensSeed$700MAug 2026
    AlphaSense logoAlphaSenseSeries F$350MJun 2026
    AlphaSense logoAlphaSenseSeries C$350MJan 2026
    AlphaSense logoAlphaSenseGrowth$100MJan 2026
    Lumilens logoLumilensSeries C$700MJan 2026
    Scope logoScopeSeries A$20MJan 2026
    Presence logoPresenceSeries C$22MJan 2026
    Riva logoRivaPre-Seed$3MAug 2025
    Heron logoHeronSeries A$16MJul 2025
    Veza logoVezaSeries D$108MJan 2025
    Exein logoExeinSeries B—Jan 2025
    GeoWealth logoGeoWealthSeries C$38MJan 2025
    Octaura logoOctauraGrowth$46.5MJan 2025
    Meter logoMeterUnknown$170MJan 2025
    Animaj logoAnimajUnknown—Jan 2025
    Vultr logoVultrGrowth$333MDec 2024
    Lightning AI logoLightning AISeries C$50MNov 2024
    Cresta logoCrestaSeries D$125MNov 2024
    Vanta logoVantaSeries C$150MJul 2024
    Partior logoPartiorSeries B$60MJul 2024
    Natural Cycles logoNatural CyclesSeries C—May 2024
    Enlaza Therapeutics logoEnlaza TherapeuticsSeries A$100MApr 2024
    Arcadia logoArcadiaGrowth$50MApr 2024
    Page 1 of 4

    Top Co-Investors

    Last updated: 20 October 2026